Which Orange Book patents cover Lucentis (ranibizumab), and when do they expire?
Lucentis (ranibizumab) has multiple listed Orange Book–type patent entries. Under the Hatch-Waxman/BPCA framework, biosimilar approval timing depends on (1) which patents are listed for the reference product and (2) whether any are still within their enforceable term (or are covered by any regulatory stay/eligibility timing).
I don’t have the underlying Orange Book patent list and specific expiration dates in the information provided here, so I can’t accurately name the exact patents or their BPCA expiration dates for Lucentis without those data. If you share the Orange Book entries (or a link/screenshot listing the Lucentis patent numbers and expiration dates), I can map each patent to the likely biosimilar timing implications.
How does BPCA affect when a ranibizumab biosimilar can launch?
For biologics subject to the Biologics Price Competition and Innovation Act (BPCIA), the “launch clock” is tied to reference-product exclusivities and patent protections rather than only FDA review timing. In practice, biosimilars can face a delayed launch date if:
- patents remain enforceable (including those listed in the Orange Book for the reference product where applicable in the Hatch-Waxman framework), and/or
- FDA approval pathways and litigation-triggered stays delay entry until patent litigation milestones are resolved.
To give a precise “earliest possible launch” date for Lucentis biosimilars, you need the exact patent expiration dates and whether any Orange Book/BPCA protections apply to that particular product presentation.
What does “Orange Book patents BPCA expiration” mean in the Lucentis context?
Users often ask this when trying to reconcile two systems:
- The Orange Book lists patents for NDA/brand drugs under Hatch-Waxman (with BPCA-style patent term adjustments/extensions affecting some drug-product exclusivity timelines).
- Biosimilars are regulated under BPCIA, but patent litigation and market-entry timing often still references patent expiration periods connected to the reference product’s protected terms.
For Lucentis, the key task is identifying which specific patent entries (and their adjusted/extended terms) are still active at the time the biosimilar applicant would otherwise be able to commercialize.
Do Lucentis biosimilar launch dates track the same dates as “Orange Book patent expiry”?
Not always. Even if a patent expires, launch can still be delayed by:
- other still-active patents covering formulation, method-of-use, or device/packaging,
- FDA exclusivity rules (depending on product-specific status), and
- litigation-driven stays or outcomes.
So the correct method is to build a “patent fence” from the full list of relevant expirations, then overlay the biosimilar approval/market-entry rules.
What should you look for to answer this precisely for ranibizumab?
To produce the exact “Lucentis Orange Book patents, BPCA expiration, and biosimilar timing” answer, the missing inputs are the specific Orange Book entries. You’d typically need:
- the listed patent numbers tied to Lucentis,
- each patent’s expiration date,
- any BPCA-related adjustments/extensions shown for those patents, and
- which patent(s) are relevant to the particular biosimilar’s proposed reference product/labeling.
If you paste the Lucentis Orange Book entries, I can finish the job
Send either:
- the Orange Book patent list for Lucentis (patent numbers + expiration dates, including any BPCA notes), or
- the Orange Book link text you have,
and tell me which biosimilar you’re focusing on (if you have one). I’ll then compute the effective earliest launch window based on the expiration set you provide and explain which patents drive timing delays.
Sources
No sources were provided in the prompt, and I don’t have the Lucentis Orange Book/BPCA patent table needed to cite specific patent numbers and expiration dates.